Abbott Laboratories Corporation

Neurocrine Biosciences, Inc.

Wesley J Dwight

Anil Vasudevan

Fortuna Haviv

Chen Chen

Warren Stanfield Wade

Zhiqiang Guo

Ramin Faghih

Fabio C Tucci

Charles Q Huang

Dongpei Wu

Jonathan Greer

Yongsheng Chen

Youssef L Bennani

Scott E Conner

Milan Bruncko

Lawrence A Black

Huaqing Liu

Rolf E Swenson

Henry Q Zhang

Charles J Nichols

John A DeMattei

Michele A Kaminski

Lisa Marie Frey

Robert Gentles

Bradley W Crawford

Kathleen M Phelan

Yousseff L Bennani

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, R, R, Rand X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods related thereto

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications

Cyclic and bicyclic diamino histamine-3 receptor antagonists

The present invention relates to a class of pentapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

Pentapeptide LHRH antagonists

The present invention relates to a class of heptapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

C-terminus modified heptapeptide LHRH analogs

Tetrahydroisoquinoline derivatives of the formula: ##STR1## or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.

Tetrahydroisoquinoline derivatives as LHRH antagonists

Growing community of inventors

San Diego, CA, United States of America

Wesley J Dwight